Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., trading under the ticker ARYB, is a clinical-stage biopharmaceutical company focused on neuroscience, with a pipeline targeting conditions including schizophrenia, Parkinson's disease, and epilepsy. The company became publicly listed through its merger with ARYA Sciences Acquisition Corp II, a life sciences-focused blank-check vehicle sponsored by Perceptive Advisors that completed its IPO in 2020. The de-SPAC transaction closed later that year, and as of the 8-K filing dated June 8, 2023, Cerevel remained an active Nasdaq-listed company advancing its neuroscience drug candidates. ARYA Sciences Acquisition Corp II was one of several SPAC vehicles in the ARYA Sciences series managed by Perceptive. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on Cerevel and the broader SPAC universe.